Antiplatelet and Antithrombotic Therapy After Patent Foramen Oval and Atrial Septal Defect Closure

Author(s): Maria Drakopoulou*, Stergios Soulaidopoulos, Konstantinos Stathogiannis, Georgios Oikonomou, Aggelos Papanikolaou, Konstantinos Toutouzas, Dimitrios Tousoulis

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 23 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Pathologies of the atrial septum include different interatrial communications varying from patent foramen ovale (PFO) to actual defects. Atrial septal defects (ASDs) may be localized within the fossa ovalis such as the secundum type ASD or outside the region of fossa ovalis, such as the ostium primum defect and sinus venosus defect. Over the last decades, the percutaneous closure of interatrial shunts has become a feasible and safe method. During these procedures, the delicate balance between thrombotic risk, device sealing process and bleeding risk is crucial. In this review, we sought to describe current available data on the antiplatelet and antithrombotic management of patients after percutaneous ASD or PFO closure.

Keywords: Patent foramen ovale, atrial septal defect, occluder devices, structural heart disease, fossa ovalis, interatrial shunts.

[1]
Rigatelli G, Zuin M. Leonardo da Vinci and patent foramen ovale: An historical perspective. Int J Cardiol 2016; 222: 826.
[http://dx.doi.org/10.1016/j.ijcard.2016.08.079] [PMID: 27522382]
[2]
Ebeid MR. Percutaneous catheter closure of secundum atrial septal defects: a review. J Invasive Cardiol 2002; 14(1): 25-31.
[PMID: 11773692]
[3]
Nassif M, Abdelghani M, Bouma BJ, et al. Historical developments of atrial septal defect closure devices: what we learn from the past. Expert Rev Med Devices 2016; 13(6): 555-68.
[http://dx.doi.org/10.1080/17434440.2016.1182860] [PMID: 27112301]
[4]
Oster M, Bhatt AB, Zaragoza-Macias E, Dendukuri N, Marelli A. Interventional Therapy Versus Medical Therapy for Secundum Atrial Septal Defect: A Systematic Review (Part 2) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73(12): 1579-95.
[http://dx.doi.org/10.1016/j.jacc.2018.08.1032] [PMID: 30121241]
[5]
Thilén M, Christersson C, Dellborg M, Mattsson E, Trzebiatowska-Krzynska A, Thilén U. Catheter closure of atrial septal defect in the elderly (≥65years). A worthwhile procedure. Int J Cardiol 2016; 218: 25-30.
[http://dx.doi.org/10.1016/j.ijcard.2016.05.024] [PMID: 27232907]
[6]
Darmoch F, Al-Khadra Y, Bacha HM, Soud M, Alraies MC. Closing the gap on patent foramen ovale and cryptogenic stroke. Expert Rev Cardiovasc Ther 2019; 17(6): 389-94.
[http://dx.doi.org/10.1080/14779072.2019.1627875] [PMID: 31184225]
[7]
Nietlispach F, Meier B. Percutaneous closure of patent foramen ovale: an underutilized prevention? Eur Heart J 2016; 37(26): 2023-8.
[http://dx.doi.org/10.1093/eurheartj/ehv376] [PMID: 26248568]
[8]
Moore J, Hegde S, El-Said H, et al. ACC IMPACT Steering Committee. Transcatheter device closure of atrial septal defects: a safety review. JACC Cardiovasc Interv 2013; 6(5): 433-42.
[http://dx.doi.org/10.1016/j.jcin.2013.02.005] [PMID: 23702008]
[9]
Giordano M, Gaio G, Santoro G, et al. Patent foramen ovale with complex anatomy: Comparison of two different devices (Amplatzer Septal Occluder device and Amplatzer PFO Occluder device 30/35). Int J Cardiol 2019; 279: 47-50.
[http://dx.doi.org/10.1016/j.ijcard.2018.10.053] [PMID: 30344060]
[10]
Madhkour R, Wahl A, Praz F, Meier B. Amplatzer patent foramen ovale occluder: safety and efficacy. Expert Rev Med Devices 2019; 16(3): 173-82.
[http://dx.doi.org/10.1080/17434440.2019.1581060] [PMID: 30741039]
[11]
Giblett JP, Abdul-Samad O, Shapiro LM, Rana BS, Calvert PA. Patent Foramen Ovale Closure in 2019. Interv Cardiol (Lond) 2019; 14(1): 34-41.
[http://dx.doi.org/10.15420/icr.2018.33.2] [PMID: 30858890]
[12]
Pristipino C, Sievert H, D’Ascenzo F, et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. Eur Heart J 2018.
[PMID: 30358849]
[13]
Kharouf R, Luxenberg DM, Khalid O, Abdulla R. Atrial septal defect: spectrum of care. Pediatr Cardiol 2008; 29(2): 271-80.
[http://dx.doi.org/10.1007/s00246-007-9052-8] [PMID: 17955282]
[14]
Steinberg DH, Pichard AD, Satler LF, et al. Patent foramen ovale closure: past, present and future. Expert Rev Cardiovasc Ther 2007; 5(5): 881-91.
[http://dx.doi.org/10.1586/14779072.5.5.881] [PMID: 17867918]
[15]
Rigatelli G, Cardaioli P, Hijazi ZM. Contemporary clinical management of atrial septal defects in the adult. Expert Rev Cardiovasc Ther 2007; 5(6): 1135-46.
[http://dx.doi.org/10.1586/14779072.5.6.1135] [PMID: 18035929]
[16]
Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73(12): e81-e192.
[http://dx.doi.org/10.1016/j.jacc.2018.08.1029] [PMID: 30121239]
[17]
Collado FMS, Poulin M-F, Murphy JJ, Jneid H, Kavinsky CJ. Patent Foramen Ovale Closure for Stroke Prevention and Other Disorders. J Am Heart Assoc 2018; 7(12): 7.
[http://dx.doi.org/10.1161/JAHA.117.007146] [PMID: 29910192]
[18]
Sherman JM, Hagler DJ, Cetta F. Thrombosis after septal closure device placement: a review of the current literature. Catheter Cardiovasc Interv 2004; 63(4): 486-9.
[http://dx.doi.org/10.1002/ccd.20220] [PMID: 15558771]
[19]
Krumsdorf U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 2004; 43(2): 302-9.
[http://dx.doi.org/10.1016/j.jacc.2003.10.030] [PMID: 14736453]
[20]
Bonou M, Lampropoulos KM, Barbetseas J. Thrombus formation 10 years after placement of an atrial septal secundum defect closure device. Eur Heart J 2012; 33(6): 704.
[http://dx.doi.org/10.1093/eurheartj/ehr313] [PMID: 21900292]
[21]
Brandt RR, Neumann T, Neuzner J, Rau M, Faude I, Hamm CW. Transcatheter closure of atrial septal defect and patent foramen ovale in adult patients using the Amplatzer occlusion device: no evidence for thrombus deposition with antiplatelet agents. J Am Soc Echocardiogr 2002; 15(10 Pt 1): 1094-8.
[http://dx.doi.org/10.1067/mje.2002.121666] [PMID: 12373252]
[22]
Anzai H, Child J, Natterson B, et al. Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices. Am J Cardiol 2004; 93(4): 426-31.
[http://dx.doi.org/10.1016/j.amjcard.2003.10.036] [PMID: 14969615]
[23]
Mir H, Siemieniuk RAC, Ge L, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence. BMJ Open 2018; 8(7)e023761
[http://dx.doi.org/10.1136/bmjopen-2018-023761] [PMID: 30049703]
[24]
Kuijpers T, Spencer FA, Siemieniuk RAC, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. BMJ 2018; 362: k2515.
[http://dx.doi.org/10.1136/bmj.k2515] [PMID: 30045912]
[25]
Chessa M, Carminati M, Butera G, et al. Early and late complications associated with transcatheter occlusion of secundum atrial septal defect. J Am Coll Cardiol 2002; 39(6): 1061-5.
[http://dx.doi.org/10.1016/S0735-1097(02)01711-4] [PMID: 11897451]
[26]
Wintzer-Wehekind J, Alperi A, Houde C, et al. Long-Term Follow-Up After Closure of Patent Foramen Ovale in Patients With Cryptogenic Embolism. J Am Coll Cardiol 2019; 73(3): 278-87.
[http://dx.doi.org/10.1016/j.jacc.2018.10.061] [PMID: 30678757]
[27]
Turc G, Calvet D, Guérin P, Sroussi M, Chatellier G, Mas JL. CLOSE Investigators. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study. J Am Heart Assoc 2018; 7(12): 7.
[http://dx.doi.org/10.1161/JAHA.117.008356] [PMID: 29910193]
[28]
Astroulakis Z, El-Gamel A, Hill JM. Failed endothelialisation of a percutaneous atrial septal defect closure device. Heart 2008; 94(5): 580.
[http://dx.doi.org/10.1136/hrt.2007.135251] [PMID: 18411351]
[29]
Sigler M, Jux C, Ewert P. Histopathological workup of an Amplatzer atrial septal defect occluder after surgical removal. Pediatr Cardiol 2006; 27(6): 775-6.
[http://dx.doi.org/10.1007/s00246-006-1413-1] [PMID: 17031717]
[30]
Belohlavek M, Foley DA, Gerber TC, Greenleaf JF, Seward JB. Three-dimensional ultrasound imaging of the atrial septum: normal and pathologic anatomy. J Am Coll Cardiol 1993; 22(6): 1673-8.
[http://dx.doi.org/10.1016/0735-1097(93)90594-Q] [PMID: 8227837]
[31]
Naqvi N, McCarthy KP, Ho SY. Anatomy of the atrial septum and interatrial communications. J Thorac Dis 2018; 10(Suppl. 24): S2837-47.
[http://dx.doi.org/10.21037/jtd.2018.02.18] [PMID: 30305943]
[32]
Bechis MZ, Rubenson DS, Price MJ. Imaging Assessment of the Interatrial Septum for Transcatheter Atrial Septal Defect and Patent Foramen Ovale Closure. Interv Cardiol Clin 2017; 6(4): 505-24.
[http://dx.doi.org/10.1016/j.iccl.2017.05.004] [PMID: 28886842]
[33]
Asrress KN, Marciniak M, Marciniak A, Rajani R, Clapp B. Patent foramen ovale: the current state of play. Heart 2015; 101(23): 1916-25.
[http://dx.doi.org/10.1136/heartjnl-2015-307639] [PMID: 26487104]
[34]
Tobis J, Shenoda M. Percutaneous treatment of patent foramen ovale and atrial septal defects. J Am Coll Cardiol 2012; 60(18): 1722-32.
[http://dx.doi.org/10.1016/j.jacc.2012.01.086] [PMID: 23040567]
[35]
Alkhouli M, Sievert H, Holmes DR. Patent foramen ovale closure for secondary stroke prevention. Eur Heart J 2019; 40(28): 2339-50.
[http://dx.doi.org/10.1093/eurheartj/ehz157] [PMID: 30957864]
[36]
Shanks M, Manawadu D, Vonder Muhll I, Khan K, Becher H, Choy J. Detection of patent foramen ovale by 3D echocardiography. JACC Cardiovasc Imaging 2012; 5(3): 329-31.
[http://dx.doi.org/10.1016/j.jcmg.2011.09.024] [PMID: 22421180]
[37]
Falanga G, Carerj S, Oreto G, Khandheria B, Zito C. How to Understand Patent Foramen Ovale Clinical Significance - Part II: Therapeutic Strategies in Cryptogenic Stroke. J Cardiovasc Echogr 2015; 25(2): 46-53.
[PMID: 28465931]
[38]
Falanga G, Carerj S, Oreto G, Khandheria BK, Zito C. How to Understand Patent Foramen Ovale Clinical Significance: Part I. J Cardiovasc Echogr 2014; 24(4): 114-21.
[http://dx.doi.org/10.4103/2211-4122.147202] [PMID: 28465918]
[39]
Abdi S, Kiani R, Momtahen M, et al. Percutaneous device closure for secundum-type atrial septal defect: short and intermediate-term results. Arch Iran Med 2012; 15(11): 693-5.
[PMID: 23102246]
[40]
Acar P, Massabuau P, Elbaz M. Real-time 3D transoesophageal echocardiography for guiding Amplatzer septal occluder device deployment in an adult patient with atrial septal defect. Eur J Echocardiogr 2008; 9(6): 822-3.
[PMID: 18579488]
[41]
Acar P, Saliba Z, Bonhoeffer P, et al. Influence of atrial septal defect anatomy in patient selection and assessment of closure with the Cardioseal device; a three-dimensional transoesophageal echocardiographic reconstruction. Eur Heart J 2000; 21(7): 573-81.
[http://dx.doi.org/10.1053/euhj.1999.1855] [PMID: 10775012]
[42]
Pristipino C, Sievert H, D’Ascenzo F, et al. European Association of Percutaneous Cardiovascular Interventions (EAPCI); European Stroke Organisation (ESO); European Heart Rhythm Association (EHRA); European Association for Cardiovascular Imaging (EACVI); Association for European Paediatric and Congenital Cardiology (AEPC); ESC Working group on GUCH; ESC Working group on Thrombosis; European Haematological Society (EHA). European position paper on the management of patients with patent foramen ovale General approach and left circulation thromboembolismEuroIntervention 2019; 14(13): 1389-402.
[http://dx.doi.org/10.4244/EIJ-D-18-00622] [PMID: 30141306]
[43]
Pan G, Xie Z-F, Zhang Y, Long S-C, Xu X-P, Zhang Z-W. Platelet activation through the efficacy of aspirin in congenital heart disease patients undergoing transcatheter closure of atrial septal defects or ventricular septal defects. Genet Test Mol Biomarkers 2014; 18(12): 832-8.
[http://dx.doi.org/10.1089/gtmb.2014.0206] [PMID: 25330142]
[44]
Ding W, Kou J, Meng H, et al. Procoagulant activity induced by transcatheter closure of atrial septal defects is associated with exposure of phosphatidylserine on microparticles, platelets and red blood cells. Thromb Res 2015; 136(2): 354-60.
[http://dx.doi.org/10.1016/j.thromres.2015.06.015] [PMID: 26099643]
[45]
Zeng X-C, Wu W-F, Huang K, Guo S-L, Liu T-W. Enhanced prothrombin formation and platelet activation in Chinese patients after transcatheter closure of atrial septal defect. Clin Cardiol 2010; 33(7): E6-9.
[http://dx.doi.org/10.1002/clc.20752] [PMID: 20552683]
[46]
Rodés-Cabau J, O’Hara G, Paradis J-M, et al. Changes in Coagulation and Platelet Activation Markers Following Transcatheter Left Atrial Appendage Closure. Am J Cardiol 2017; 120(1): 87-91.
[http://dx.doi.org/10.1016/j.amjcard.2017.03.253] [PMID: 28495432]
[47]
Bédard E, Rodés-Cabau J, Houde C, et al. Enhanced thrombogenesis but not platelet activation is associated with transcatheter closure of patent foramen ovale in patients with cryptogenic stroke. Stroke 2007; 38(1): 100-4.
[http://dx.doi.org/10.1161/01.STR.0000251712.55322.69] [PMID: 17122434]
[48]
Rodés-Cabau J, Palacios A, Palacio C, et al. Assessment of the markers of platelet and coagulation activation following transcatheter closure of atrial septal defects. Int J Cardiol 2005; 98(1): 107-12.
[http://dx.doi.org/10.1016/j.ijcard.2004.03.022] [PMID: 15676174]
[49]
Lock JE, Rome JJ, Davis R, et al. Transcatheter closure of atrial septal defects. Experimental studies. Circulation 1989; 79(5): 1091-9.
[http://dx.doi.org/10.1161/01.CIR.79.5.1091] [PMID: 2713975]
[50]
Das GS, Voss G, Jarvis G, Wyche K, Gunther R, Wilson RF. Experimental atrial septal defect closure with a new, transcatheter, self-centering device. Circulation 1993; 88(4 Pt 1): 1754-64.
[http://dx.doi.org/10.1161/01.CIR.88.4.1754] [PMID: 8403322]
[51]
Li B-N, Xie Y-M, Xie Z-F, et al. Study of biodegradable occluder of atrial septal defect in a porcine model. Catheter Cardiovasc Interv 2019; 93(1): E38-45.
[PMID: 30196545]
[52]
Sharafuddin MJ, Gu X, Titus JL, Urness M, Cervera-Ceballos JJ, Amplatz K. Transvenous closure of secundum atrial septal defects: preliminary results with a new self-expanding nitinol prosthesis in a swine model. Circulation 1997; 95(8): 2162-8.
[http://dx.doi.org/10.1161/01.CIR.95.8.2162] [PMID: 9133527]
[53]
Marchese N, Pacilli MA, Inchingolo V, Fanelli R, Loperfido F, Vigna C. Residual shunt after percutaneous closure of patent foramen ovale with AMPLATZER occluder devices - influence of anatomic features: a transcranial Doppler and intracardiac echocardiography study. EuroIntervention 2013; 9(3): 382-8.
[http://dx.doi.org/10.4244/EIJV9I3A61] [PMID: 23872652]
[54]
Agarwal S, Bajaj NS, Kumbhani DJ, Tuzcu EM, Kapadia SR. Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism. JACC Cardiovasc Interv 2012; 5(7): 777-89.
[http://dx.doi.org/10.1016/j.jcin.2012.02.021] [PMID: 22814784]
[55]
Anzola GP, Morandi E, Casilli F, Onorato E. Does transcatheter closure of patent foramen ovale really “shut the door?” A prospective study with transcranial Doppler. Stroke 2004; 35(9): 2140-4.
[http://dx.doi.org/10.1161/01.STR.0000137764.07815.de] [PMID: 15284445]
[56]
Anzola GP, Zavarize P, Morandi E, Rozzini L, Parrinello G. Transcranial Doppler and risk of recurrence in patients with stroke and patent foramen ovale. Eur J Neurol 2003; 10(2): 129-35.
[http://dx.doi.org/10.1046/j.1468-1331.2003.00561.x] [PMID: 12603287]
[57]
Alaeddini J, Feghali G, Jenkins S, Ramee S, White C, Abi-Samra F. Frequency of atrial tachyarrhythmias following transcatheter closure of patent foramen ovale. J Invasive Cardiol 2006; 18(8): 365-8.
[PMID: 16877784]
[58]
Bhindi R. Percutaneous closure of patent foramen ovale and the risk of atrial fibrillation. Catheter Cardiovasc Interv 2010; 75(2): 301.
[http://dx.doi.org/10.1002/ccd.22253] [PMID: 20049956]
[59]
Berger F, Vogel M, Kretschmar O, Dave H, Prêtre R, Dodge-Khatami A. Arrhythmias in patients with surgically treated atrial septal defects. Swiss Med Wkly 2005; 135(11-12): 175-8.
[PMID: 15846530]
[60]
Blake GE, Lakkireddy D. Atrial Septal Defect and Atrial Fibrillation: The Known and Unknown. J Atr Fibrillation 2008; 1(3): 45.
[http://dx.doi.org/10.4022/jafib.v1i1.390] [PMID: 28496588]
[61]
Elgendy AY, Elgendy IY, Mojadidi MK, et al. New-onset atrial fibrillation following percutaneous patent foramen ovale closure: a systematic review and meta-analysis of randomised trials. EuroIntervention 2019; 14(17): 1788-90.
[http://dx.doi.org/10.4244/EIJ-D-18-00767] [PMID: 30327284]
[62]
Duong P, Ferguson LP, Lord S, et al. Atrial arrhythmia after transcatheter closure of secundum atrial septal defects in patients ≥40 years of age. Europace 2017; 19(8): 1322-6.
[http://dx.doi.org/10.1093/europace/euw186] [PMID: 27702856]
[63]
Meier B, Kalesan B, Mattle HP, et al. PC Trial Investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368(12): 1083-91.
[http://dx.doi.org/10.1056/NEJMoa1211716] [PMID: 23514285]
[64]
Carroll JD, Saver JL, Thaler DE, et al. RESPECT Investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368(12): 1092-100.
[http://dx.doi.org/10.1056/NEJMoa1301440] [PMID: 23514286]
[65]
Søndergaard L, Kasner SE, Rhodes JF, et al. Gore REDUCE Clinical Study Investigators. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med 2017; 377(11): 1033-42.
[http://dx.doi.org/10.1056/NEJMoa1707404] [PMID: 28902580]
[66]
Furlan AJ, Reisman M, Massaro J, et al. CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366(11): 991-9.
[http://dx.doi.org/10.1056/NEJMoa1009639] [PMID: 22417252]
[67]
Mas J-L, Derumeaux G, Guillon B, et al. CLOSE Investigators. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med 2017; 377(11): 1011-21.
[http://dx.doi.org/10.1056/NEJMoa1705915] [PMID: 28902593]
[68]
Lee PH, Song J-K, Kim JS, et al. Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial. J Am Coll Cardiol 2018; 71(20): 2335-42.
[http://dx.doi.org/10.1016/j.jacc.2018.02.046] [PMID: 29544871]
[69]
Hviid CVB, Simonsen CZ, Hvas A-M. Recurrence Risk in Patients with Cryptogenic Stroke, Patent Foramen Ovale, and Thrombophilia: A Systematic Review and Meta-Analysis. Thromb Haemost 2019; 119(11): 1839-48.
[http://dx.doi.org/10.1055/s-0039-1693739] [PMID: 31378004]
[70]
Shah R, Currie AD, Khan S, Ashraf F. An updated meta-analysis comparing percutaneous device closure with medical therapy alone for patent foramen ovale in patients with cryptogenic stroke. Cardiovasc Revasc Med 2019; 20(10): 926-7.
[http://dx.doi.org/10.1016/j.carrev.2019.07.008] [PMID: 31375464]
[71]
Oster M, Bhatt AB, Zaragoza-Macias E, Dendukuri N, Marelli A. Interventional Therapy Versus Medical Therapy for Secundum Atrial Septal Defect: A Systematic Review (Part 2) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139(14): e814-30.
[http://dx.doi.org/10.1161/CIR.0000000000000605] [PMID: 30586769]
[72]
Saver JL, Carroll JD, Thaler DE, et al. RESPECT Investigators. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med 2017; 377(11): 1022-32.
[http://dx.doi.org/10.1056/NEJMoa1610057] [PMID: 28902590]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 23
Year: 2020
Published on: 26 April, 2020
Page: [2769 - 2779]
Pages: 11
DOI: 10.2174/1385272824999200427083838
Price: $65

Article Metrics

PDF: 29
HTML: 4